nodes	percent_of_prediction	percent_of_DWPC	metapath
Trazodone—HTR2B—Sorafenib—liver cancer	0.216	0.273	CbGbCtD
Trazodone—HTR2C—Sorafenib—liver cancer	0.141	0.178	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0917	0.116	CbGbCtD
Trazodone—CYP3A7—Sorafenib—liver cancer	0.0917	0.116	CbGbCtD
Trazodone—CYP3A5—Sorafenib—liver cancer	0.0688	0.0869	CbGbCtD
Trazodone—ABCB1—Sorafenib—liver cancer	0.0447	0.0565	CbGbCtD
Trazodone—CYP2D6—Sorafenib—liver cancer	0.0422	0.0533	CbGbCtD
Trazodone—ABCB1—Doxorubicin—liver cancer	0.0272	0.0343	CbGbCtD
Trazodone—CYP3A4—Sorafenib—liver cancer	0.0268	0.0339	CbGbCtD
Trazodone—CYP2D6—Doxorubicin—liver cancer	0.0256	0.0323	CbGbCtD
Trazodone—CYP3A4—Doxorubicin—liver cancer	0.0163	0.0206	CbGbCtD
Trazodone—Amylase increased—Sorafenib—liver cancer	0.00413	0.0326	CcSEcCtD
Trazodone—Leukocytoclastic vasculitis—Sorafenib—liver cancer	0.00401	0.0317	CcSEcCtD
Trazodone—Suicide—Sorafenib—liver cancer	0.00379	0.0299	CcSEcCtD
Trazodone—Completed suicide—Sorafenib—liver cancer	0.00334	0.0264	CcSEcCtD
Trazodone—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.00217	0.0172	CcSEcCtD
Trazodone—Cardiac failure congestive—Sorafenib—liver cancer	0.00157	0.0124	CcSEcCtD
Trazodone—Hyponatraemia—Sorafenib—liver cancer	0.00143	0.0113	CcSEcCtD
Trazodone—Abdominal discomfort—Sorafenib—liver cancer	0.00118	0.00934	CcSEcCtD
Trazodone—Eruption—Epirubicin—liver cancer	0.00118	0.00933	CcSEcCtD
Trazodone—Psoriasis—Epirubicin—liver cancer	0.00115	0.00913	CcSEcCtD
Trazodone—Erectile dysfunction—Sorafenib—liver cancer	0.00113	0.00897	CcSEcCtD
Trazodone—Weight decreased—Sorafenib—liver cancer	0.00111	0.00882	CcSEcCtD
Trazodone—Eruption—Doxorubicin—liver cancer	0.00109	0.00863	CcSEcCtD
Trazodone—Acute coronary syndrome—Sorafenib—liver cancer	0.00108	0.00856	CcSEcCtD
Trazodone—Myocardial infarction—Sorafenib—liver cancer	0.00108	0.00852	CcSEcCtD
Trazodone—Hypokinesia—Epirubicin—liver cancer	0.00108	0.0085	CcSEcCtD
Trazodone—Jaundice—Sorafenib—liver cancer	0.00107	0.00847	CcSEcCtD
Trazodone—Psoriasis—Doxorubicin—liver cancer	0.00107	0.00845	CcSEcCtD
Trazodone—Hypokinesia—Doxorubicin—liver cancer	0.000995	0.00787	CcSEcCtD
Trazodone—Tinnitus—Sorafenib—liver cancer	0.00092	0.00727	CcSEcCtD
Trazodone—Flushing—Sorafenib—liver cancer	0.000915	0.00724	CcSEcCtD
Trazodone—Arrhythmia—Sorafenib—liver cancer	0.000881	0.00697	CcSEcCtD
Trazodone—Alopecia—Sorafenib—liver cancer	0.000872	0.00689	CcSEcCtD
Trazodone—Dysgeusia—Sorafenib—liver cancer	0.000841	0.00665	CcSEcCtD
Trazodone—Jaundice cholestatic—Epirubicin—liver cancer	0.000826	0.00653	CcSEcCtD
Trazodone—Vasodilation procedure—Epirubicin—liver cancer	0.000826	0.00653	CcSEcCtD
Trazodone—Vasodilation—Epirubicin—liver cancer	0.000826	0.00653	CcSEcCtD
Trazodone—Ventricular extrasystoles—Epirubicin—liver cancer	0.000804	0.00635	CcSEcCtD
Trazodone—Hyperbilirubinaemia—Epirubicin—liver cancer	0.000798	0.00631	CcSEcCtD
Trazodone—Anaemia—Sorafenib—liver cancer	0.000794	0.00628	CcSEcCtD
Trazodone—Dyskinesia—Epirubicin—liver cancer	0.000772	0.00611	CcSEcCtD
Trazodone—Syncope—Sorafenib—liver cancer	0.00077	0.00609	CcSEcCtD
Trazodone—Dysarthria—Epirubicin—liver cancer	0.000767	0.00607	CcSEcCtD
Trazodone—Jaundice cholestatic—Doxorubicin—liver cancer	0.000764	0.00604	CcSEcCtD
Trazodone—Vasodilation procedure—Doxorubicin—liver cancer	0.000764	0.00604	CcSEcCtD
Trazodone—Vasodilation—Doxorubicin—liver cancer	0.000764	0.00604	CcSEcCtD
Trazodone—Loss of consciousness—Sorafenib—liver cancer	0.000755	0.00597	CcSEcCtD
Trazodone—Atrioventricular block—Epirubicin—liver cancer	0.000748	0.00592	CcSEcCtD
Trazodone—Gait disturbance—Epirubicin—liver cancer	0.000744	0.00588	CcSEcCtD
Trazodone—Ventricular extrasystoles—Doxorubicin—liver cancer	0.000744	0.00588	CcSEcCtD
Trazodone—Hypertension—Sorafenib—liver cancer	0.000741	0.00586	CcSEcCtD
Trazodone—Coordination abnormal—Epirubicin—liver cancer	0.000739	0.00584	CcSEcCtD
Trazodone—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000739	0.00584	CcSEcCtD
Trazodone—Arthralgia—Sorafenib—liver cancer	0.000731	0.00578	CcSEcCtD
Trazodone—Myalgia—Sorafenib—liver cancer	0.000731	0.00578	CcSEcCtD
Trazodone—Ventricular tachycardia—Epirubicin—liver cancer	0.000726	0.00574	CcSEcCtD
Trazodone—Abnormal dreams—Epirubicin—liver cancer	0.000717	0.00567	CcSEcCtD
Trazodone—Dry mouth—Sorafenib—liver cancer	0.000715	0.00565	CcSEcCtD
Trazodone—Dyskinesia—Doxorubicin—liver cancer	0.000715	0.00565	CcSEcCtD
Trazodone—Dysarthria—Doxorubicin—liver cancer	0.00071	0.00561	CcSEcCtD
Trazodone—Salivary hypersecretion—Epirubicin—liver cancer	0.000705	0.00557	CcSEcCtD
Trazodone—Atrioventricular block—Doxorubicin—liver cancer	0.000692	0.00548	CcSEcCtD
Trazodone—Shock—Sorafenib—liver cancer	0.000689	0.00545	CcSEcCtD
Trazodone—Gait disturbance—Doxorubicin—liver cancer	0.000688	0.00544	CcSEcCtD
Trazodone—Coordination abnormal—Doxorubicin—liver cancer	0.000684	0.00541	CcSEcCtD
Trazodone—Ventricular tachycardia—Doxorubicin—liver cancer	0.000672	0.00531	CcSEcCtD
Trazodone—Dry eye—Epirubicin—liver cancer	0.00067	0.0053	CcSEcCtD
Trazodone—Anorexia—Sorafenib—liver cancer	0.000668	0.00528	CcSEcCtD
Trazodone—Abnormal dreams—Doxorubicin—liver cancer	0.000664	0.00525	CcSEcCtD
Trazodone—Bladder pain—Epirubicin—liver cancer	0.000656	0.00519	CcSEcCtD
Trazodone—Salivary hypersecretion—Doxorubicin—liver cancer	0.000652	0.00516	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000638	0.00505	CcSEcCtD
Trazodone—Mental disability—Epirubicin—liver cancer	0.00063	0.00498	CcSEcCtD
Trazodone—Dyspnoea—Sorafenib—liver cancer	0.000625	0.00494	CcSEcCtD
Trazodone—Dry eye—Doxorubicin—liver cancer	0.00062	0.00491	CcSEcCtD
Trazodone—Decreased appetite—Sorafenib—liver cancer	0.000609	0.00482	CcSEcCtD
Trazodone—Bladder pain—Doxorubicin—liver cancer	0.000607	0.0048	CcSEcCtD
Trazodone—Fatigue—Sorafenib—liver cancer	0.000604	0.00478	CcSEcCtD
Trazodone—Photosensitivity—Epirubicin—liver cancer	0.0006	0.00474	CcSEcCtD
Trazodone—Pain—Sorafenib—liver cancer	0.000599	0.00474	CcSEcCtD
Trazodone—Constipation—Sorafenib—liver cancer	0.000599	0.00474	CcSEcCtD
Trazodone—Eye pain—Epirubicin—liver cancer	0.000584	0.00462	CcSEcCtD
Trazodone—Mental disability—Doxorubicin—liver cancer	0.000583	0.00461	CcSEcCtD
Trazodone—Cardiac failure congestive—Epirubicin—liver cancer	0.000581	0.00459	CcSEcCtD
Trazodone—Gastrointestinal pain—Sorafenib—liver cancer	0.000573	0.00453	CcSEcCtD
Trazodone—Increased appetite—Epirubicin—liver cancer	0.000561	0.00443	CcSEcCtD
Trazodone—Urticaria—Sorafenib—liver cancer	0.000557	0.0044	CcSEcCtD
Trazodone—Photosensitivity—Doxorubicin—liver cancer	0.000555	0.00439	CcSEcCtD
Trazodone—Body temperature increased—Sorafenib—liver cancer	0.000554	0.00438	CcSEcCtD
Trazodone—Abdominal pain—Sorafenib—liver cancer	0.000554	0.00438	CcSEcCtD
Trazodone—Eye pain—Doxorubicin—liver cancer	0.00054	0.00427	CcSEcCtD
Trazodone—Cerebrovascular accident—Epirubicin—liver cancer	0.000538	0.00425	CcSEcCtD
Trazodone—Lethargy—Epirubicin—liver cancer	0.000538	0.00425	CcSEcCtD
Trazodone—Cardiac failure congestive—Doxorubicin—liver cancer	0.000538	0.00425	CcSEcCtD
Trazodone—Hyponatraemia—Epirubicin—liver cancer	0.000529	0.00418	CcSEcCtD
Trazodone—Diplopia—Epirubicin—liver cancer	0.000527	0.00417	CcSEcCtD
Trazodone—Increased appetite—Doxorubicin—liver cancer	0.000519	0.0041	CcSEcCtD
Trazodone—Migraine—Epirubicin—liver cancer	0.000519	0.0041	CcSEcCtD
Trazodone—Hypersensitivity—Sorafenib—liver cancer	0.000516	0.00408	CcSEcCtD
Trazodone—Asthenia—Sorafenib—liver cancer	0.000503	0.00398	CcSEcCtD
Trazodone—Cardiac arrest—Epirubicin—liver cancer	0.000501	0.00396	CcSEcCtD
Trazodone—Lethargy—Doxorubicin—liver cancer	0.000498	0.00393	CcSEcCtD
Trazodone—Cerebrovascular accident—Doxorubicin—liver cancer	0.000498	0.00393	CcSEcCtD
Trazodone—Pruritus—Sorafenib—liver cancer	0.000496	0.00392	CcSEcCtD
Trazodone—Ataxia—Epirubicin—liver cancer	0.000495	0.00392	CcSEcCtD
Trazodone—Hyponatraemia—Doxorubicin—liver cancer	0.00049	0.00387	CcSEcCtD
Trazodone—Diplopia—Doxorubicin—liver cancer	0.000488	0.00386	CcSEcCtD
Trazodone—Orthostatic hypotension—Epirubicin—liver cancer	0.000481	0.00381	CcSEcCtD
Trazodone—Migraine—Doxorubicin—liver cancer	0.00048	0.00379	CcSEcCtD
Trazodone—Diarrhoea—Sorafenib—liver cancer	0.000479	0.00379	CcSEcCtD
Trazodone—Cardiac arrest—Doxorubicin—liver cancer	0.000464	0.00367	CcSEcCtD
Trazodone—Dizziness—Sorafenib—liver cancer	0.000463	0.00366	CcSEcCtD
Trazodone—Ataxia—Doxorubicin—liver cancer	0.000458	0.00362	CcSEcCtD
Trazodone—Vomiting—Sorafenib—liver cancer	0.000446	0.00352	CcSEcCtD
Trazodone—Orthostatic hypotension—Doxorubicin—liver cancer	0.000445	0.00352	CcSEcCtD
Trazodone—Rash—Sorafenib—liver cancer	0.000442	0.00349	CcSEcCtD
Trazodone—Dermatitis—Sorafenib—liver cancer	0.000441	0.00349	CcSEcCtD
Trazodone—Headache—Sorafenib—liver cancer	0.000439	0.00347	CcSEcCtD
Trazodone—Pollakiuria—Epirubicin—liver cancer	0.000421	0.00333	CcSEcCtD
Trazodone—Nausea—Sorafenib—liver cancer	0.000416	0.00329	CcSEcCtD
Trazodone—Photosensitivity reaction—Epirubicin—liver cancer	0.000416	0.00329	CcSEcCtD
Trazodone—Weight increased—Epirubicin—liver cancer	0.000414	0.00328	CcSEcCtD
Trazodone—Weight decreased—Epirubicin—liver cancer	0.000412	0.00326	CcSEcCtD
Trazodone—Drowsiness—Epirubicin—liver cancer	0.000406	0.00321	CcSEcCtD
Trazodone—Jaundice—Epirubicin—liver cancer	0.000396	0.00313	CcSEcCtD
Trazodone—Sweating—Epirubicin—liver cancer	0.000389	0.00308	CcSEcCtD
Trazodone—Pollakiuria—Doxorubicin—liver cancer	0.000389	0.00308	CcSEcCtD
Trazodone—Haematuria—Epirubicin—liver cancer	0.000387	0.00306	CcSEcCtD
Trazodone—Photosensitivity reaction—Doxorubicin—liver cancer	0.000385	0.00304	CcSEcCtD
Trazodone—Weight increased—Doxorubicin—liver cancer	0.000384	0.00303	CcSEcCtD
Trazodone—Weight decreased—Doxorubicin—liver cancer	0.000381	0.00301	CcSEcCtD
Trazodone—Drowsiness—Doxorubicin—liver cancer	0.000376	0.00297	CcSEcCtD
Trazodone—Bradycardia—Epirubicin—liver cancer	0.000371	0.00293	CcSEcCtD
Trazodone—Jaundice—Doxorubicin—liver cancer	0.000366	0.0029	CcSEcCtD
Trazodone—Hypoaesthesia—Epirubicin—liver cancer	0.000363	0.00287	CcSEcCtD
Trazodone—Sweating—Doxorubicin—liver cancer	0.00036	0.00285	CcSEcCtD
Trazodone—Haematuria—Doxorubicin—liver cancer	0.000358	0.00283	CcSEcCtD
Trazodone—Visual impairment—Epirubicin—liver cancer	0.000351	0.00278	CcSEcCtD
Trazodone—Bradycardia—Doxorubicin—liver cancer	0.000343	0.00272	CcSEcCtD
Trazodone—Tinnitus—Epirubicin—liver cancer	0.00034	0.00269	CcSEcCtD
Trazodone—Flushing—Epirubicin—liver cancer	0.000338	0.00268	CcSEcCtD
Trazodone—Hypoaesthesia—Doxorubicin—liver cancer	0.000336	0.00265	CcSEcCtD
Trazodone—Chills—Epirubicin—liver cancer	0.000327	0.00259	CcSEcCtD
Trazodone—Arrhythmia—Epirubicin—liver cancer	0.000326	0.00257	CcSEcCtD
Trazodone—Visual impairment—Doxorubicin—liver cancer	0.000325	0.00257	CcSEcCtD
Trazodone—Alopecia—Epirubicin—liver cancer	0.000322	0.00255	CcSEcCtD
Trazodone—Tinnitus—Doxorubicin—liver cancer	0.000314	0.00249	CcSEcCtD
Trazodone—Flushing—Doxorubicin—liver cancer	0.000313	0.00248	CcSEcCtD
Trazodone—Flatulence—Epirubicin—liver cancer	0.000313	0.00247	CcSEcCtD
Trazodone—Tension—Epirubicin—liver cancer	0.000311	0.00246	CcSEcCtD
Trazodone—Dysgeusia—Epirubicin—liver cancer	0.000311	0.00246	CcSEcCtD
Trazodone—Nervousness—Epirubicin—liver cancer	0.000308	0.00244	CcSEcCtD
Trazodone—Back pain—Epirubicin—liver cancer	0.000307	0.00243	CcSEcCtD
Trazodone—Chills—Doxorubicin—liver cancer	0.000303	0.00239	CcSEcCtD
Trazodone—Arrhythmia—Doxorubicin—liver cancer	0.000301	0.00238	CcSEcCtD
Trazodone—Vision blurred—Epirubicin—liver cancer	0.000299	0.00236	CcSEcCtD
Trazodone—Alopecia—Doxorubicin—liver cancer	0.000298	0.00236	CcSEcCtD
Trazodone—Ill-defined disorder—Epirubicin—liver cancer	0.000294	0.00233	CcSEcCtD
Trazodone—Anaemia—Epirubicin—liver cancer	0.000293	0.00232	CcSEcCtD
Trazodone—Agitation—Epirubicin—liver cancer	0.000292	0.00231	CcSEcCtD
Trazodone—Flatulence—Doxorubicin—liver cancer	0.000289	0.00229	CcSEcCtD
Trazodone—Tension—Doxorubicin—liver cancer	0.000288	0.00228	CcSEcCtD
Trazodone—Dysgeusia—Doxorubicin—liver cancer	0.000288	0.00227	CcSEcCtD
Trazodone—Malaise—Epirubicin—liver cancer	0.000286	0.00226	CcSEcCtD
Trazodone—Nervousness—Doxorubicin—liver cancer	0.000285	0.00225	CcSEcCtD
Trazodone—Vertigo—Epirubicin—liver cancer	0.000285	0.00225	CcSEcCtD
Trazodone—Syncope—Epirubicin—liver cancer	0.000285	0.00225	CcSEcCtD
Trazodone—Back pain—Doxorubicin—liver cancer	0.000284	0.00225	CcSEcCtD
Trazodone—Palpitations—Epirubicin—liver cancer	0.00028	0.00222	CcSEcCtD
Trazodone—Loss of consciousness—Epirubicin—liver cancer	0.000279	0.00221	CcSEcCtD
Trazodone—Vision blurred—Doxorubicin—liver cancer	0.000277	0.00219	CcSEcCtD
Trazodone—Hypertension—Epirubicin—liver cancer	0.000274	0.00217	CcSEcCtD
Trazodone—Ill-defined disorder—Doxorubicin—liver cancer	0.000272	0.00215	CcSEcCtD
Trazodone—Anaemia—Doxorubicin—liver cancer	0.000271	0.00215	CcSEcCtD
Trazodone—Chest pain—Epirubicin—liver cancer	0.00027	0.00214	CcSEcCtD
Trazodone—Myalgia—Epirubicin—liver cancer	0.00027	0.00214	CcSEcCtD
Trazodone—Arthralgia—Epirubicin—liver cancer	0.00027	0.00214	CcSEcCtD
Trazodone—Agitation—Doxorubicin—liver cancer	0.00027	0.00213	CcSEcCtD
Trazodone—Anxiety—Epirubicin—liver cancer	0.000269	0.00213	CcSEcCtD
Trazodone—Discomfort—Epirubicin—liver cancer	0.000267	0.00211	CcSEcCtD
Trazodone—Malaise—Doxorubicin—liver cancer	0.000265	0.00209	CcSEcCtD
Trazodone—Dry mouth—Epirubicin—liver cancer	0.000264	0.00209	CcSEcCtD
Trazodone—Vertigo—Doxorubicin—liver cancer	0.000264	0.00209	CcSEcCtD
Trazodone—Syncope—Doxorubicin—liver cancer	0.000263	0.00208	CcSEcCtD
Trazodone—Confusional state—Epirubicin—liver cancer	0.000261	0.00206	CcSEcCtD
Trazodone—Palpitations—Doxorubicin—liver cancer	0.000259	0.00205	CcSEcCtD
Trazodone—Oedema—Epirubicin—liver cancer	0.000259	0.00205	CcSEcCtD
Trazodone—Loss of consciousness—Doxorubicin—liver cancer	0.000258	0.00204	CcSEcCtD
Trazodone—Shock—Epirubicin—liver cancer	0.000255	0.00201	CcSEcCtD
Trazodone—Hypertension—Doxorubicin—liver cancer	0.000254	0.002	CcSEcCtD
Trazodone—Tachycardia—Epirubicin—liver cancer	0.000253	0.002	CcSEcCtD
Trazodone—Hyperhidrosis—Epirubicin—liver cancer	0.00025	0.00198	CcSEcCtD
Trazodone—Chest pain—Doxorubicin—liver cancer	0.00025	0.00198	CcSEcCtD
Trazodone—Myalgia—Doxorubicin—liver cancer	0.00025	0.00198	CcSEcCtD
Trazodone—Arthralgia—Doxorubicin—liver cancer	0.00025	0.00198	CcSEcCtD
Trazodone—Anxiety—Doxorubicin—liver cancer	0.000249	0.00197	CcSEcCtD
Trazodone—Discomfort—Doxorubicin—liver cancer	0.000247	0.00195	CcSEcCtD
Trazodone—Anorexia—Epirubicin—liver cancer	0.000247	0.00195	CcSEcCtD
Trazodone—Dry mouth—Doxorubicin—liver cancer	0.000244	0.00193	CcSEcCtD
Trazodone—Hypotension—Epirubicin—liver cancer	0.000242	0.00191	CcSEcCtD
Trazodone—Confusional state—Doxorubicin—liver cancer	0.000242	0.00191	CcSEcCtD
Trazodone—Oedema—Doxorubicin—liver cancer	0.00024	0.00189	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000236	0.00187	CcSEcCtD
Trazodone—Shock—Doxorubicin—liver cancer	0.000236	0.00186	CcSEcCtD
Trazodone—Insomnia—Epirubicin—liver cancer	0.000234	0.00185	CcSEcCtD
Trazodone—Tachycardia—Doxorubicin—liver cancer	0.000234	0.00185	CcSEcCtD
Trazodone—Paraesthesia—Epirubicin—liver cancer	0.000233	0.00184	CcSEcCtD
Trazodone—Hyperhidrosis—Doxorubicin—liver cancer	0.000232	0.00183	CcSEcCtD
Trazodone—Dyspnoea—Epirubicin—liver cancer	0.000231	0.00183	CcSEcCtD
Trazodone—Somnolence—Epirubicin—liver cancer	0.00023	0.00182	CcSEcCtD
Trazodone—Anorexia—Doxorubicin—liver cancer	0.000228	0.00181	CcSEcCtD
Trazodone—Decreased appetite—Epirubicin—liver cancer	0.000225	0.00178	CcSEcCtD
Trazodone—Hypotension—Doxorubicin—liver cancer	0.000224	0.00177	CcSEcCtD
Trazodone—Fatigue—Epirubicin—liver cancer	0.000223	0.00177	CcSEcCtD
Trazodone—Constipation—Epirubicin—liver cancer	0.000221	0.00175	CcSEcCtD
Trazodone—Pain—Epirubicin—liver cancer	0.000221	0.00175	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000218	0.00173	CcSEcCtD
Trazodone—Insomnia—Doxorubicin—liver cancer	0.000217	0.00171	CcSEcCtD
Trazodone—Paraesthesia—Doxorubicin—liver cancer	0.000215	0.0017	CcSEcCtD
Trazodone—Dyspnoea—Doxorubicin—liver cancer	0.000214	0.00169	CcSEcCtD
Trazodone—Feeling abnormal—Epirubicin—liver cancer	0.000213	0.00169	CcSEcCtD
Trazodone—Somnolence—Doxorubicin—liver cancer	0.000213	0.00168	CcSEcCtD
Trazodone—Gastrointestinal pain—Epirubicin—liver cancer	0.000212	0.00167	CcSEcCtD
Trazodone—Decreased appetite—Doxorubicin—liver cancer	0.000208	0.00165	CcSEcCtD
Trazodone—Fatigue—Doxorubicin—liver cancer	0.000207	0.00163	CcSEcCtD
Trazodone—Urticaria—Epirubicin—liver cancer	0.000206	0.00163	CcSEcCtD
Trazodone—Constipation—Doxorubicin—liver cancer	0.000205	0.00162	CcSEcCtD
Trazodone—Pain—Doxorubicin—liver cancer	0.000205	0.00162	CcSEcCtD
Trazodone—Abdominal pain—Epirubicin—liver cancer	0.000205	0.00162	CcSEcCtD
Trazodone—Body temperature increased—Epirubicin—liver cancer	0.000205	0.00162	CcSEcCtD
Trazodone—Feeling abnormal—Doxorubicin—liver cancer	0.000197	0.00156	CcSEcCtD
Trazodone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000196	0.00155	CcSEcCtD
Trazodone—Hypersensitivity—Epirubicin—liver cancer	0.000191	0.00151	CcSEcCtD
Trazodone—Urticaria—Doxorubicin—liver cancer	0.00019	0.00151	CcSEcCtD
Trazodone—Abdominal pain—Doxorubicin—liver cancer	0.000189	0.0015	CcSEcCtD
Trazodone—Body temperature increased—Doxorubicin—liver cancer	0.000189	0.0015	CcSEcCtD
Trazodone—Asthenia—Epirubicin—liver cancer	0.000186	0.00147	CcSEcCtD
Trazodone—Pruritus—Epirubicin—liver cancer	0.000183	0.00145	CcSEcCtD
Trazodone—Diarrhoea—Epirubicin—liver cancer	0.000177	0.0014	CcSEcCtD
Trazodone—Hypersensitivity—Doxorubicin—liver cancer	0.000177	0.0014	CcSEcCtD
Trazodone—Asthenia—Doxorubicin—liver cancer	0.000172	0.00136	CcSEcCtD
Trazodone—Dizziness—Epirubicin—liver cancer	0.000171	0.00135	CcSEcCtD
Trazodone—Pruritus—Doxorubicin—liver cancer	0.00017	0.00134	CcSEcCtD
Trazodone—Vomiting—Epirubicin—liver cancer	0.000165	0.0013	CcSEcCtD
Trazodone—Diarrhoea—Doxorubicin—liver cancer	0.000164	0.0013	CcSEcCtD
Trazodone—Rash—Epirubicin—liver cancer	0.000163	0.00129	CcSEcCtD
Trazodone—Dermatitis—Epirubicin—liver cancer	0.000163	0.00129	CcSEcCtD
Trazodone—Headache—Epirubicin—liver cancer	0.000162	0.00128	CcSEcCtD
Trazodone—Dizziness—Doxorubicin—liver cancer	0.000158	0.00125	CcSEcCtD
Trazodone—Nausea—Epirubicin—liver cancer	0.000154	0.00122	CcSEcCtD
Trazodone—Vomiting—Doxorubicin—liver cancer	0.000152	0.0012	CcSEcCtD
Trazodone—Rash—Doxorubicin—liver cancer	0.000151	0.00119	CcSEcCtD
Trazodone—Dermatitis—Doxorubicin—liver cancer	0.000151	0.00119	CcSEcCtD
Trazodone—Headache—Doxorubicin—liver cancer	0.00015	0.00119	CcSEcCtD
Trazodone—Nausea—Doxorubicin—liver cancer	0.000142	0.00113	CcSEcCtD
Trazodone—CYP2D6—Metabolism—GSTM1—liver cancer	9.66e-06	0.000118	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MMP9—liver cancer	9.62e-06	0.000117	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—F2—liver cancer	9.62e-06	0.000117	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CDKN1A—liver cancer	9.59e-06	0.000117	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—ALB—liver cancer	9.56e-06	0.000116	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—BRAF—liver cancer	9.51e-06	0.000116	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—BRAF—liver cancer	9.49e-06	0.000116	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MAPK8—liver cancer	9.36e-06	0.000114	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—AKT1—liver cancer	9.33e-06	0.000114	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—BRAF—liver cancer	9.31e-06	0.000114	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—PIK3CA—liver cancer	9.26e-06	0.000113	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	9.22e-06	0.000112	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—APC—liver cancer	9.21e-06	0.000112	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	9.21e-06	0.000112	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—RAF1—liver cancer	9.19e-06	0.000112	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—CYP1A1—liver cancer	9.16e-06	0.000112	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—RAF1—liver cancer	9.15e-06	0.000111	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PSMD10—liver cancer	9.11e-06	0.000111	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PSMA4—liver cancer	9.11e-06	0.000111	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—MTHFR—liver cancer	9.06e-06	0.00011	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MTOR—liver cancer	8.98e-06	0.000109	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PIK3CB—liver cancer	8.98e-06	0.000109	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PIK3CB—liver cancer	8.93e-06	0.000109	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MTOR—liver cancer	8.93e-06	0.000109	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CD—liver cancer	8.9e-06	0.000108	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PPARA—liver cancer	8.89e-06	0.000108	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CD—liver cancer	8.88e-06	0.000108	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CD—liver cancer	8.87e-06	0.000108	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GOT2—liver cancer	8.87e-06	0.000108	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	8.81e-06	0.000107	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—SERPINE1—liver cancer	8.8e-06	0.000107	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—PIK3CA—liver cancer	8.79e-06	0.000107	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—SERPINE1—liver cancer	8.78e-06	0.000107	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—ALB—liver cancer	8.76e-06	0.000107	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CD—liver cancer	8.71e-06	0.000106	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—KRAS—liver cancer	8.71e-06	0.000106	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—KRAS—liver cancer	8.69e-06	0.000106	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—BRAF—liver cancer	8.65e-06	0.000105	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—VEGFA—liver cancer	8.64e-06	0.000105	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—PIK3CA—liver cancer	8.63e-06	0.000105	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—SERPINE1—liver cancer	8.62e-06	0.000105	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—HRAS—liver cancer	8.57e-06	0.000104	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—STAT3—liver cancer	8.55e-06	0.000104	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—MTHFR—liver cancer	8.54e-06	0.000104	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—KRAS—liver cancer	8.53e-06	0.000104	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—HRAS—liver cancer	8.53e-06	0.000104	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CB—liver cancer	8.44e-06	0.000103	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CDKN1B—liver cancer	8.42e-06	0.000103	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CDKN1B—liver cancer	8.38e-06	0.000102	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PPARA—liver cancer	8.38e-06	0.000102	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CYP2E1—liver cancer	8.34e-06	0.000102	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—AKT1—liver cancer	8.33e-06	0.000102	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—AKT1—liver cancer	8.29e-06	0.000101	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CASP3—liver cancer	8.26e-06	0.000101	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IL2—liver cancer	8.24e-06	0.0001	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CASP3—liver cancer	8.21e-06	0.0001	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—IL6—liver cancer	8.2e-06	0.0001	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IL2—liver cancer	8.2e-06	9.99e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—IL6—liver cancer	8.16e-06	9.94e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	8.09e-06	9.86e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CCND1—liver cancer	8.04e-06	9.79e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—JUN—liver cancer	8.02e-06	9.77e-05	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	8.02e-06	9.77e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	8.01e-06	9.76e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	8e-06	9.75e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CCND1—liver cancer	7.99e-06	9.74e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—PIK3CA—liver cancer	7.98e-06	9.73e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—JUN—liver cancer	7.98e-06	9.72e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CTNNB1—liver cancer	7.96e-06	9.7e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MYC—liver cancer	7.95e-06	9.69e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—RAF1—liver cancer	7.94e-06	9.68e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—TGFB1—liver cancer	7.93e-06	9.66e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—RAF1—liver cancer	7.93e-06	9.66e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—KRAS—liver cancer	7.92e-06	9.66e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CTNNB1—liver cancer	7.92e-06	9.65e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	7.84e-06	9.55e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MMP9—liver cancer	7.8e-06	9.51e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CYCS—liver cancer	7.8e-06	9.5e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—RAF1—liver cancer	7.78e-06	9.48e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CDKN1A—liver cancer	7.77e-06	9.47e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MMP9—liver cancer	7.76e-06	9.46e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MTOR—liver cancer	7.75e-06	9.45e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CB—liver cancer	7.75e-06	9.45e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MTOR—liver cancer	7.74e-06	9.43e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CB—liver cancer	7.74e-06	9.43e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CDKN1A—liver cancer	7.73e-06	9.42e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CB—liver cancer	7.73e-06	9.42e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GGT1—liver cancer	7.65e-06	9.33e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GOT1—liver cancer	7.65e-06	9.33e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CG—liver cancer	7.61e-06	9.28e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	7.59e-06	9.25e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MTOR—liver cancer	7.59e-06	9.25e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MAPK8—liver cancer	7.59e-06	9.25e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—AKT1—liver cancer	7.57e-06	9.22e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MAPK8—liver cancer	7.55e-06	9.2e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—AKT1—liver cancer	7.53e-06	9.17e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—HRAS—liver cancer	7.4e-06	9.02e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—HRAS—liver cancer	7.39e-06	9e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PPARG—liver cancer	7.35e-06	8.96e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—KRAS—liver cancer	7.34e-06	8.95e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	7.28e-06	8.87e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CDKN1B—liver cancer	7.28e-06	8.87e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CDKN1B—liver cancer	7.26e-06	8.85e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—HRAS—liver cancer	7.25e-06	8.83e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—RAF1—liver cancer	7.23e-06	8.81e-05	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—AKT1—liver cancer	7.2e-06	8.77e-05	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—AKT1—liver cancer	7.18e-06	8.75e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CG—liver cancer	7.18e-06	8.74e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CASP3—liver cancer	7.13e-06	8.69e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	7.13e-06	8.68e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IL2—liver cancer	7.12e-06	8.68e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CASP3—liver cancer	7.12e-06	8.67e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IL2—liver cancer	7.11e-06	8.66e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—IL6—liver cancer	7.09e-06	8.64e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—IL6—liver cancer	7.07e-06	8.62e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	7.05e-06	8.6e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MTOR—liver cancer	7.05e-06	8.6e-05	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	7.05e-06	8.59e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—VEGFA—liver cancer	7.01e-06	8.54e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CASP3—liver cancer	6.98e-06	8.51e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IL2—liver cancer	6.97e-06	8.5e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—VEGFA—liver cancer	6.97e-06	8.49e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CCND1—liver cancer	6.94e-06	8.46e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—IL6—liver cancer	6.94e-06	8.46e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—STAT3—liver cancer	6.94e-06	8.45e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—JUN—liver cancer	6.93e-06	8.44e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CCND1—liver cancer	6.93e-06	8.44e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PPARG—liver cancer	6.92e-06	8.44e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—JUN—liver cancer	6.91e-06	8.42e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—STAT3—liver cancer	6.9e-06	8.41e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CTNNB1—liver cancer	6.87e-06	8.38e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GSTP1—liver cancer	6.87e-06	8.38e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CTNNB1—liver cancer	6.86e-06	8.36e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CCND1—liver cancer	6.8e-06	8.28e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—JUN—liver cancer	6.78e-06	8.27e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—HMOX1—liver cancer	6.78e-06	8.26e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—PIK3CA—liver cancer	6.75e-06	8.22e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MMP9—liver cancer	6.74e-06	8.21e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—HRAS—liver cancer	6.74e-06	8.21e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	6.73e-06	8.2e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MMP9—liver cancer	6.73e-06	8.2e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CDKN1A—liver cancer	6.72e-06	8.18e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CDKN1A—liver cancer	6.7e-06	8.17e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CD—liver cancer	6.69e-06	8.16e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	6.62e-06	8.07e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—ALB—liver cancer	6.61e-06	8.05e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MMP9—liver cancer	6.6e-06	8.04e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	6.58e-06	8.01e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MAPK8—liver cancer	6.56e-06	7.99e-05	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	6.55e-06	7.98e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MAPK8—liver cancer	6.54e-06	7.97e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—AKT1—liver cancer	6.54e-06	7.97e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—TP53—liver cancer	6.53e-06	7.95e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—AKT1—liver cancer	6.52e-06	7.95e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PIK3CA—liver cancer	6.52e-06	7.95e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CASP3—liver cancer	6.49e-06	7.91e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IL2—liver cancer	6.48e-06	7.9e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—IL6—liver cancer	6.45e-06	7.86e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MYC—liver cancer	6.45e-06	7.85e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—TGFB1—liver cancer	6.43e-06	7.84e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MAPK8—liver cancer	6.42e-06	7.82e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MYC—liver cancer	6.41e-06	7.81e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—AKT1—liver cancer	6.4e-06	7.8e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TGFB1—liver cancer	6.4e-06	7.8e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GSTM1—liver cancer	6.32e-06	7.7e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CCND1—liver cancer	6.32e-06	7.7e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CD—liver cancer	6.31e-06	7.69e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—JUN—liver cancer	6.3e-06	7.68e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	6.25e-06	7.62e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—HRAS—liver cancer	6.24e-06	7.61e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—ALB—liver cancer	6.23e-06	7.59e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MMP9—liver cancer	6.13e-06	7.47e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	6.11e-06	7.45e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—VEGFA—liver cancer	6.05e-06	7.38e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—VEGFA—liver cancer	6.04e-06	7.36e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—STAT3—liver cancer	5.99e-06	7.3e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CYP1A1—liver cancer	5.99e-06	7.3e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—STAT3—liver cancer	5.98e-06	7.29e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—IL6—liver cancer	5.97e-06	7.28e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MAPK8—liver cancer	5.96e-06	7.27e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—KRAS—liver cancer	5.96e-06	7.26e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—AKT1—liver cancer	5.95e-06	7.25e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—VEGFA—liver cancer	5.93e-06	7.22e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—KRAS—liver cancer	5.93e-06	7.22e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—STAT3—liver cancer	5.87e-06	7.15e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CB—liver cancer	5.83e-06	7.11e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—MTHFR—liver cancer	5.58e-06	6.8e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MYC—liver cancer	5.57e-06	6.79e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MYC—liver cancer	5.56e-06	6.77e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TGFB1—liver cancer	5.56e-06	6.77e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TGFB1—liver cancer	5.54e-06	6.75e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—AKT1—liver cancer	5.51e-06	6.72e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—VEGFA—liver cancer	5.51e-06	6.71e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CB—liver cancer	5.5e-06	6.7e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PPARA—liver cancer	5.48e-06	6.68e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PIK3CA—liver cancer	5.47e-06	6.67e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MYC—liver cancer	5.45e-06	6.64e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—STAT3—liver cancer	5.45e-06	6.64e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PIK3CA—liver cancer	5.44e-06	6.63e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TGFB1—liver cancer	5.44e-06	6.63e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—AKT1—liver cancer	5.33e-06	6.49e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—TP53—liver cancer	5.29e-06	6.45e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TP53—liver cancer	5.27e-06	6.42e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—KRAS—liver cancer	5.15e-06	6.27e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CA—liver cancer	5.14e-06	6.27e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—KRAS—liver cancer	5.13e-06	6.26e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MYC—liver cancer	5.07e-06	6.17e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—HRAS—liver cancer	5.06e-06	6.17e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TGFB1—liver cancer	5.05e-06	6.16e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—KRAS—liver cancer	5.04e-06	6.14e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—HRAS—liver cancer	5.04e-06	6.14e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IL6—liver cancer	4.85e-06	5.9e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IL6—liver cancer	4.82e-06	5.87e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CA—liver cancer	4.73e-06	5.76e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CA—liver cancer	4.72e-06	5.75e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CA—liver cancer	4.71e-06	5.74e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CG—liver cancer	4.69e-06	5.72e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—KRAS—liver cancer	4.68e-06	5.7e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	4.63e-06	5.64e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TP53—liver cancer	4.57e-06	5.57e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TP53—liver cancer	4.56e-06	5.56e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PPARG—liver cancer	4.53e-06	5.52e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TP53—liver cancer	4.48e-06	5.46e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—AKT1—liver cancer	4.47e-06	5.45e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—AKT1—liver cancer	4.45e-06	5.42e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—HRAS—liver cancer	4.37e-06	5.33e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—HRAS—liver cancer	4.36e-06	5.32e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	4.3e-06	5.24e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—HRAS—liver cancer	4.28e-06	5.22e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—AKT1—liver cancer	4.2e-06	5.12e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IL6—liver cancer	4.19e-06	5.1e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IL6—liver cancer	4.18e-06	5.09e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TP53—liver cancer	4.16e-06	5.07e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CD—liver cancer	4.12e-06	5.03e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IL6—liver cancer	4.1e-06	4.99e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ALB—liver cancer	4.07e-06	4.96e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—HRAS—liver cancer	3.98e-06	4.85e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—AKT1—liver cancer	3.86e-06	4.71e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—AKT1—liver cancer	3.85e-06	4.7e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—AKT1—liver cancer	3.85e-06	4.69e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IL6—liver cancer	3.81e-06	4.64e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—AKT1—liver cancer	3.78e-06	4.61e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CB—liver cancer	3.59e-06	4.38e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CA—liver cancer	3.56e-06	4.33e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—AKT1—liver cancer	3.51e-06	4.28e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CA—liver cancer	3.35e-06	4.08e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—AKT1—liver cancer	2.91e-06	3.54e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—AKT1—liver cancer	2.74e-06	3.34e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CA—liver cancer	2.19e-06	2.67e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—AKT1—liver cancer	1.79e-06	2.18e-05	CbGpPWpGaD
